NASDAQ:CLGN CollPlant Biotechnologies (CLGN) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free CLGN Stock Alerts $5.41 +0.01 (+0.19%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$5.36▼$5.4250-Day Range$4.71▼$5.6852-Week Range$4.22▼$8.90Volume1,040 shsAverage Volume8,114 shsMarket Capitalization$61.94 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get CollPlant Biotechnologies alerts: Email Address CollPlant Biotechnologies MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside103.3% Upside$11.00 Price TargetShort InterestHealthy0.14% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.42) to ($0.52) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.55 out of 5 starsMedical Sector784th out of 909 stocksSurgical Appliances & Supplies Industry16th out of 18 stocks 3.5 Analyst's Opinion Consensus RatingCollPlant Biotechnologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageCollPlant Biotechnologies has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.14% of the float of CollPlant Biotechnologies has been sold short.Short Interest Ratio / Days to CoverCollPlant Biotechnologies has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CollPlant Biotechnologies has recently increased by 33.33%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCollPlant Biotechnologies does not currently pay a dividend.Dividend GrowthCollPlant Biotechnologies does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CLGN. Previous Next 1.9 News and Social Media Coverage News SentimentCollPlant Biotechnologies has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for CollPlant Biotechnologies this week, compared to 0 articles on an average week.MarketBeat FollowsOnly 1 people have added CollPlant Biotechnologies to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CollPlant Biotechnologies insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.60% of the stock of CollPlant Biotechnologies is held by insiders.Percentage Held by InstitutionsOnly 21.69% of the stock of CollPlant Biotechnologies is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for CollPlant Biotechnologies are expected to grow in the coming year, from ($1.42) to ($0.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CollPlant Biotechnologies is -8.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CollPlant Biotechnologies is -8.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCollPlant Biotechnologies has a P/B Ratio of 2.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad TradeSmithThe A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...Click here to see Louis' new video for yourself. About CollPlant Biotechnologies Stock (NASDAQ:CLGN)CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; Tel Aviv University; Sheba Medical Center; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.Read More CLGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CLGN Stock News HeadlinesApril 23, 2024 | finance.yahoo.comCollPlant Biotechnologies (NASDAQ:CLGN) Is In A Strong Position To Grow Its BusinessApril 15, 2024 | americanbankingnews.comCollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Short Interest UpdateApril 24, 2024 | Crypto Swap Profits (Ad)Did You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.April 8, 2024 | msn.comCollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Q4 2023 Earnings Call TranscriptApril 6, 2024 | seekingalpha.comCollPlant Biotechnologies Ltd. (CLGN) Q4 2023 Earnings Call TranscriptApril 4, 2024 | markets.businessinsider.comCollPlant Biotechnologies FY23 Net Loss NarrowsApril 4, 2024 | msn.comCLGN Stock Earnings: CollPlant Biotechnologies Misses EPS, Misses Revenue for Q4 2023April 4, 2024 | msn.comUS Index Futures Rise, Oil Dips SlightlyApril 24, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.April 4, 2024 | prnewswire.comCOLLPLANT BIOTECHNOLOGIES REPORTS 2023 FULL YEAR FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATEMarch 26, 2024 | finance.yahoo.comCOLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 FULL YEAR FINANCIAL RESULTS AND CONFERENCE CALL INFORMATIONFebruary 15, 2024 | finance.yahoo.comCollPlant Issues Letter to ShareholdersFebruary 15, 2024 | prnewswire.comCollPlant Issues Letter to ShareholdersFebruary 13, 2024 | au.finance.yahoo.comCOLLPLANT BIOTECH. IS-,01 (CPT.MU)January 8, 2024 | finance.yahoo.comCollPlant's CEO to Present at the Octane Aesthetic Tech Forum Conference, in Newport Beach, CaliforniaJanuary 2, 2024 | finance.yahoo.comCollPlant Biotechnologies Begins Preclinical Trial with Commercial-Size, Regenerative Breast ImplantsDecember 2, 2023 | benzinga.comCollPlant Biotechnologies Stock (NASDAQ:CLGN), Analyst Ratings, Price Targets, PredictionsDecember 1, 2023 | finance.yahoo.comCollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Q3 2023 Earnings Call TranscriptNovember 29, 2023 | benzinga.comRecap: CollPlant Biotechnologies Q3 EarningsNovember 29, 2023 | msn.comCollPlant Biotechnologies Non-GAAP EPS of -$0.35November 29, 2023 | finance.yahoo.comCollPlant Biotechnologies Announces Third Quarter Financial Results for 2023November 9, 2023 | finance.yahoo.comCOLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 THIRD QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATIONNovember 3, 2023 | finance.yahoo.comWill CollPlant Biotechnologies (NASDAQ:CLGN) Spend Its Cash Wisely?November 1, 2023 | msn.comCollPlant says patent granted in U.S. for photocurable dermal fillerNovember 1, 2023 | finance.yahoo.comCollPlant Biotechnologies Announces Patent Granted in U.S. for Photocurable Dermal FillerOctober 5, 2023 | finance.yahoo.comShareholders in CollPlant Biotechnologies (NASDAQ:CLGN) are in the red if they invested three years agoSeptember 21, 2023 | finance.yahoo.comCollPlant Biotechnologies Joins the United Nations Global Compact, The World's Largest Corporate Sustainability InitiativeSee More Headlines Receive CLGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CollPlant Biotechnologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/24/2023Today4/24/2024Next Earnings (Estimated)5/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical appliances & supplies Sub-IndustryN/A Current SymbolNASDAQ:CLGN CUSIPN/A CIK1631487 Webwww.collplant.com Phone972732325600Fax972-73-232-5602Employees73Year FoundedN/APrice Target and Rating Average Stock Price Target$11.00 High Stock Price Target$11.00 Low Stock Price Target$11.00 Potential Upside/Downside+103.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,020,000.00 Net Margins-64.05% Pretax Margin-64.05% Return on Equity-22.17% Return on Assets-18.84% Debt Debt-to-Equity RatioN/A Current Ratio8.62 Quick Ratio8.40 Sales & Book Value Annual Sales$10.96 million Price / Sales5.64 Cash FlowN/A Price / Cash FlowN/A Book Value$2.47 per share Price / Book2.19Miscellaneous Outstanding Shares11,450,000Free Float10,354,000Market Cap$61.83 million OptionableOptionable Beta0.24 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Yehiel Tal (Age 72)CEO & Director Comp: $865kMr. Eran Rotem CPA (Age 56)Deputy CEO & CFO Comp: $651kProf. Oded Shoseyov (Age 68)Founder & Chief Scientist Comp: $384kMr. Oren Fahimipoor (Age 42)Vice President of Operations Ms. Hadas Dreiher Horowitz (Age 47)Vice President of Human Resources Dr. Elana Gazal (Age 49)Vice President of Research & Development More ExecutivesKey CompetitorsVicarious SurgicalNYSE:RBOTMilestone ScientificNYSE:MLSSReWalk RoboticsNASDAQ:LFWDNutribandNASDAQ:NTRBEnvoy MedicalNASDAQ:COCHView All CompetitorsInstitutional OwnershipRoumell Asset Management LLCSold 145,270 shares on 2/14/2024Ownership: 3.901%Benjamin F. Edwards & Company Inc.Bought 5,100 shares on 2/6/2024Ownership: 0.452%Villere ST Denis J & Co. LLCBought 61,120 shares on 1/25/2024Ownership: 3.258%View All Institutional Transactions CLGN Stock Analysis - Frequently Asked Questions Should I buy or sell CollPlant Biotechnologies stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CollPlant Biotechnologies in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CLGN shares. View CLGN analyst ratings or view top-rated stocks. What is CollPlant Biotechnologies' stock price target for 2024? 1 brokers have issued 12-month price targets for CollPlant Biotechnologies' shares. Their CLGN share price targets range from $11.00 to $11.00. On average, they anticipate the company's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 103.3% from the stock's current price. View analysts price targets for CLGN or view top-rated stocks among Wall Street analysts. How have CLGN shares performed in 2024? CollPlant Biotechnologies' stock was trading at $6.39 on January 1st, 2024. Since then, CLGN shares have decreased by 15.3% and is now trading at $5.41. View the best growth stocks for 2024 here. Are investors shorting CollPlant Biotechnologies? CollPlant Biotechnologies saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 10,800 shares, an increase of 33.3% from the March 15th total of 8,100 shares. Based on an average trading volume of 8,200 shares, the days-to-cover ratio is currently 1.3 days. Currently, 0.1% of the shares of the company are short sold. View CollPlant Biotechnologies' Short Interest. When is CollPlant Biotechnologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 22nd 2024. View our CLGN earnings forecast. How were CollPlant Biotechnologies' earnings last quarter? CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) announced its quarterly earnings results on Thursday, August, 24th. The company reported $0.49 EPS for the quarter, topping analysts' consensus estimates of ($0.34) by $0.83. The firm had revenue of $10.18 million for the quarter, compared to analysts' expectations of $0.26 million. CollPlant Biotechnologies had a negative net margin of 64.05% and a negative trailing twelve-month return on equity of 22.17%. During the same period in the previous year, the business earned ($0.39) earnings per share. What other stocks do shareholders of CollPlant Biotechnologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other CollPlant Biotechnologies investors own include Genocea Biosciences (GNCA), Boingo Wireless (WIFI), Allena Pharmaceuticals (ALNA), Advanced Micro Devices (AMD), Energy Transfer (ET), HTG Molecular Diagnostics (HTGM), OPKO Health (OPK), Ovid Therapeutics (OVID) and When did CollPlant Biotechnologies IPO? CollPlant Biotechnologies (CLGN) raised $22 million in an IPO on Friday, December 9th 2016. The company issued 3,500,000 shares at $6.23 per share. Ladenburg Thalmann served as the underwriter for the IPO and Roth Capital Partners was co-manager. How do I buy shares of CollPlant Biotechnologies? Shares of CLGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CLGN) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyPentagon contract could send this $2 AI stock soaringBehind the MarketsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersNew Trump BombshellThe Freeport SocietyNew York goes dark, then America.Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CollPlant Biotechnologies Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
